Natera said it is preparing for faster prospective study readouts designed to clarify the clinical utility of its Signatera MRD test across tumor types. The company’s interventional “SIGNAL” portfolio is anchored by SIGNAL-ER 101, an internal study evaluating whether MRD-detected patients with HR-positive, HER2-negative breast cancer should be escalated from standard endocrine therapy to CDK4/6 inhibitors. Alongside its prospective evidence push, Natera reported second-quarter revenue growth of 38% year over year to $752.8 million, driven by increased test volumes and higher average selling price. The update reinforces the strategy of converting MRD analytics into treatment-selection protocols.